7:30 – 8:00 a.m.
Registration/Continental Breakfast
8:00 – 9:15 a.m.
Hypertension: Treating the Whole Patient
Louis Kuritzky, MD (Houston, New York, Atlanta)
Clinical Assistant Professor of Medicine, University of Florida at Gainesville
Raymond Weiss, MD (Los Angeles, Chicago)
Internal Medicine Practitioner, Advocate Christ Hospital, Oak Lawn, IL
Despite multiple advances in pharmacotherapy for hypertension, only a minority of individuals are diagnosed, treated and controlled. Recent topics of interest for better management of hypertension and its consequences include a reappraisal of the role of beta blockers in hypertension, awareness of the importance of nephropathy, and utility of 24-hr BP monitoring. This presentation will address these evolutionary steps in treatment of HTN. By participating in this activity, attendees will be able to: 1) Identify appropriate first-line antihypertensive therapies, and the data from which such decisions have evolved; 2) Recognize evolutionary therapeutic guidance suggested by the NICE HTN Rx Guidelines (2006); 3) Describe the role of modulation of other cardiovascular risk markers such as microalbuminuria and LVH in patients with HTN.
9:15 – 10:30 a.m.
Depression in the Comprehensive Care of Your Patients: A Primary Care Perspective
Gustavo Alva, MD (Atlanta)
Medical Director, ATP Clinical Research, Costa Mesa, CA
Joseph A. Lieberman III, MD (Houston, New York, Los Angeles, Chicago)
Professor of Family Medicine, Jefferson Medical College, Philadelphia
This presentation will discuss the importance of consultation and collaboration among PCPs and psychiatrists. It will help doctors gain a better understanding of the importance of early recognition of depression in the primary care setting. In addition, a number of strategies for treatment of depression will be discussed. By participating in this activity, attendees will be able to: 1) Assess the goals of therapy and the considerations for remission with standard therapies in the treatment of major depressive disorder; 2) Describe the mechanism of action of currently available agents that have been assessed for the treatment of depression and their relationship to the neurobiology of depression; and 3) Evaluate the efficacy and safety of current pharmacologic and nonpharmacologic interventions in the management of depression.
Supported by an educational grant from Eli Lilly and Company.
10:30 – 10:45 a.m.
Refreshment Break
10:45 a.m. – 12:00 p.m.
Recognizing Fibromyalgia in Primary Care
Lesley M. Arnold, MD (New York)
Associate Professor of Psychiatry, Director, Women's Health Research Program, University of Cincinnati College of Medicine
Jon W. Draud, MS, MD (Houston, Los Angeles)
Medical Director, Psychiatry and Addiction Medicine Services, Baptist Hospital; Clinical Faculty, Department of Psychiatry, Vanderbilt University, Nashville, TN
Rakesh Jain, MD, MPH (Chicago, Atlanta)
Assistant Clinical Professor of Psychiatry, University of Texas Medical School, Houston; Director, Psychiatric Drug Research, R/D Clinical Research Center, Lake Jackson, TX
Recognizing fibromyalgia in a primary care setting is challenging, especially distinguishing fibromyalgia from other conditions and overlapping symptoms. This presentation will also discuss a multidisciplinary approach to care and non-pharmacologic and pharmacologic interventions. By participating in this activity, attendees will be able to: 1) Understand the pathophysiology of fibromyalgia; 2) Identify the challenges in the diagnosis of fibromyalgia including overlapping symptomatology and comorbid conditions; and 3) Evaluate the efficacy and safety of non-pharmacologic and pharmacologic therapies for the management of fibromyalgia.
Supported by an educational grant from Eli Lilly and Company.
12:00 – 1:15 p.m.
Lunch on your own
1:15 – 2:15 p.m.
Diabetes: Achieving Excellence in Primary Care
Edward J. Shahady, MD (Houston, New York, Chicago, Atlanta)
Clinical Professor, University of Miami and University of Florida; Medical Director, Diabetes Master Clinician Program of the Florida Academy of Family Physicians, Jacksonville, FL
Dan W. Haupt, MD (Los Angeles)
Assistant Professor of Psychiatry, Washington University School of Medicine, St. Louis
This evidenced-based discussion will focus on the onset and progression of insulin resistance and subsequent metabolic defects which contribute to type 2 diabetes. Treatment options that overcome these metabolic defects, and clinician and patient barriers to achieving adherence to treatment in the primary care setting will be discussed. By participating in this activity, attendees will be able to: 1) Define excellence in diabetes care through the national guidelines; 2) Describe how insulin resistance and the metabolic defects contribute to the comorbidities in type 2 diabetes; 3) Discuss established and newer medications for diabetes; 4) Develop strategies for recognizing and overcoming patient, physician, and system barriers to achieving adherence in diabetes management in primary care.
2:15 – 3:30 p.m.
Shifting the Paradigm for ACS Management: Pathways in Achieving Improved Outcomes
Michael S. Lee, MD (All 5 Cities)
Associate Director of Interventional Cardiology Research, Division of Interventional Cardiology, UCLA School of Medicine
This presentation will provide clinicians with an increased awareness of the pathophysiological mechanisms involved in Acute Coronary Syndrome (ACS) and help them to understand the treatment paradigms for ACS. Recent practice guidelines will be outlined and emerging therapies in the management of ACS for the prevention of restenosis and stent thrombosis will be compared and contrasted. The importance of early intervention and treatment will also be discussed. By participating in this activity, attendees will be able to: 1) Identify the pathophysiological mechanisms involved in ACS; 2) Evaluate the treatment paradigms for ACS and outline recent practice guidelines; and 3) Compare and contrast emerging therapies in the management of ACS for the prevention of restenosis and stent thrombosis.
Supported by an educational grant from Daiichi Sankyo, Inc. and Eli Lilly and Company.
3:30 – 3:45 p.m.
Refreshment Break
3:45 – 5:00 p.m.
Recognizing the Complexity of Bipolar Disorder in the Primary Care Setting
Stephen V. Sobel, MD (All 5 Cities)
Clinical Instructor, UCSD School of Medicine; Consulting Psychiatrist, NFL San Diego Chargers and MLB San Diego Padres; Private Practice, Adult and Adolescent Psychiatry
A need exists for a better understanding of the roadblocks in the diagnosis and management of bipolar disorder from a primary care perspective. Patient referral and the importance of collaborative care will be discussed. In addition, tolerability profiles of antipsychotics and strategies to improve non-adherence will be discussed. By participating in this activity, attendees will be able to: 1) Compare and contrast safety and tolerability profiles of atypical antipsychotics and evaluate how to best manage metabolic side effects in individual patients; 2) Outline the current rates of adherence with therapy in the treatment of bipolar disorder and identify potential consequences of poor adherence and strategies to improve adherence rates; and 3) Describe why improving patients’ quality of life and functional outcomes should be considered as the ultimate goals of therapy.
Supported by an educational grant from Eli Lilly and Company.
5:00 p.m.
Adjourn
This is preliminary information. Topics are subject to change.
